share_log

Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy.

Benzinga ·  Jun 3 07:55

Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy. Also, the Company Announced That It Accepted an Unsolicited Offer From an Institutional Investor to Purchase 22,222,222 Shares of Stock at $9.00 per Share and Will Use the Net Proceeds to Advance Clinical Development of Ivonescimab.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment